{"id":323743,"date":"2026-10-22T12:39:39","date_gmt":"2026-10-22T07:09:39","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=323743"},"modified":"2026-10-22T12:39:39","modified_gmt":"2026-10-22T07:09:39","slug":"premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/","title":{"rendered":"3 Premium Hospital Network, Pathology Lab Chain and Regional Multi-Specialty Hospitals Stocks With a Strong Future Roadmap: Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences: ROE of 10.7% to 20.1% and FY22 to FY26 revenue CAGR of 7.6% to 23.8%. Prices as of 21 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three large hospital and pathology chain stocks to watch are Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences. Their return on equity ranges from 10.7% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 23.8%. Dr. Lal PathLabs has the highest return on equity at 20.1%, while Krishna Institute of Medical Sciences has the fastest revenue growth at 23.8% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Large hospital and pathology chain stocks let investors follow organised players that treat patients and test samples at scale. Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences cover a premium hospital network, a national pathology lab chain and a regional multi-specialty hospital group.<\/p>\n<p>This list covers three large hospital and pathology chain stocks with complete current figures: Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#What_Are_Large_Hospital_and_Pathology_Chain_Stocks\" title=\"What Are Large Hospital and Pathology Chain Stocks?\">What Are Large Hospital and Pathology Chain Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Large_Hospital_and_Pathology_Chain_Stocks_at_a_Glance\" title=\"Large Hospital and Pathology Chain Stocks at a Glance\">Large Hospital and Pathology Chain Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Why_Do_Large_Hospital_and_Pathology_Chain_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Large Hospital and Pathology Chain Stocks Have a Strong Roadmap in India?\">Why Do Large Hospital and Pathology Chain Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Why_Max_Healthcare_Institute_Features_Among_These_Large_Hospital_and_Pathology_Chain_Stocks\" title=\"Why Max Healthcare Institute Features Among These Large Hospital and Pathology Chain Stocks\">Why Max Healthcare Institute Features Among These Large Hospital and Pathology Chain Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Why_Dr_Lal_PathLabs_Features_Among_These_Large_Hospital_and_Pathology_Chain_Stocks\" title=\"Why Dr. Lal PathLabs Features Among These Large Hospital and Pathology Chain Stocks\">Why Dr. Lal PathLabs Features Among These Large Hospital and Pathology Chain Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Why_Krishna_Institute_of_Medical_Sciences_Features_Among_These_Large_Hospital_and_Pathology_Chain_Stocks\" title=\"Why Krishna Institute of Medical Sciences Features Among These Large Hospital and Pathology Chain Stocks\">Why Krishna Institute of Medical Sciences Features Among These Large Hospital and Pathology Chain Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Max_Healthcare_Institute_vs_Dr_Lal_PathLabs_vs_Krishna_Institute_of_Medical_Sciences_on_Key_Financials\" title=\"Max Healthcare Institute vs Dr. Lal PathLabs vs Krishna Institute of Medical Sciences on Key Financials\">Max Healthcare Institute vs Dr. Lal PathLabs vs Krishna Institute of Medical Sciences on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Key_Risks_to_Check_Before_Investing_in_Large_Hospital_and_Pathology_Chain_Stocks\" title=\"Key Risks to Check Before Investing in Large Hospital and Pathology Chain Stocks\">Key Risks to Check Before Investing in Large Hospital and Pathology Chain Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Final_Thoughts_on_Large_Hospital_and_Pathology_Chain_Stocks\" title=\"Final Thoughts on Large Hospital and Pathology Chain Stocks\">Final Thoughts on Large Hospital and Pathology Chain Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#What_are_large_hospital_and_pathology_chain_stocks\" title=\"What are large hospital and pathology chain stocks?\">What are large hospital and pathology chain stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Which_large_hospital_and_pathology_chain_stocks_are_covered_in_this_list\" title=\"Which large hospital and pathology chain stocks are covered in this list?\">Which large hospital and pathology chain stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Why_do_large_hospital_and_pathology_chain_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do large hospital and pathology chain stocks have a strong future roadmap in India?\">Why do large hospital and pathology chain stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#How_has_Max_Healthcare_Institute_performed_financially\" title=\"How has Max Healthcare Institute performed financially?\">How has Max Healthcare Institute performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#How_has_Dr_Lal_PathLabs_performed_financially\" title=\"How has Dr. Lal PathLabs performed financially?\">How has Dr. Lal PathLabs performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#How_has_Krishna_Institute_of_Medical_Sciences_performed_financially\" title=\"How has Krishna Institute of Medical Sciences performed financially?\">How has Krishna Institute of Medical Sciences performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#What_risks_should_investors_check_before_buying_large_hospital_and_pathology_chain_stocks\" title=\"What risks should investors check before buying large hospital and pathology chain stocks?\">What risks should investors check before buying large hospital and pathology chain stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty-hospitals-stocks-roadmap-harbinger-list\/#Is_this_list_of_large_hospital_and_pathology_chain_stocks_investment_advice\" title=\"Is this list of large hospital and pathology chain stocks investment advice?\">Is this list of large hospital and pathology chain stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Large_Hospital_and_Pathology_Chain_Stocks\"><\/span><strong>What Are Large Hospital and Pathology Chain Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Large hospital and pathology chain stocks are listed companies that run hospitals and diagnostic laboratories across several cities. Their earnings depend on bed capacity, occupancy, test volumes and the mix of procedures and tests.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Large_Hospital_and_Pathology_Chain_Stocks_at_a_Glance\"><\/span><strong>Large Hospital and Pathology Chain Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/maxhealth\/max-healthcare-institute-ltd-share-price-today\">Max Healthcare Institute<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">819.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">80,717<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">55.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.32<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr. Lal PathLabs<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,836.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">30,949<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">56.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/kims\/krishna-institute-of-medical-sciences-ltd-share-price-today\">Krishna Institute of Medical Sciences<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">674.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">28,495<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">146.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.89<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Max Healthcare Institute and Dr. Lal PathLabs trade at a P\/E below the industry P\/E, while Krishna Institute of Medical Sciences trades above it, which reflects the growth the market already expects. Readers comparing large hospital and pathology chain stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in large hospital and pathology chain stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Large_Hospital_and_Pathology_Chain_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Large Hospital and Pathology Chain Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Large hospital and pathology chain stocks have a strong roadmap in India because rising health insurance cover and a preference for trusted providers are moving patients towards organised hospitals and labs.<\/p>\n<ul>\n<li><strong>Insurance cover.<\/strong> More insured families choose organised providers for planned care.<\/li>\n<li><strong>Capacity additions.<\/strong> New beds and collection centres lift volumes in proven cities.<\/li>\n<li><strong>Preventive testing.<\/strong> Regular health checks raise the number of tests per person.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Max_Healthcare_Institute_Features_Among_These_Large_Hospital_and_Pathology_Chain_Stocks\"><\/span><strong>Why Max Healthcare Institute Features Among These Large Hospital and Pathology Chain Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the large hospital and pathology chain stocks on this list, Max Healthcare Institute runs a large network of multi-specialty hospitals concentrated in Delhi NCR, Punjab, Uttarakhand and Maharashtra, with a strong presence in oncology, cardiac sciences, neurosciences and orthopaedics.<\/p>\n<p>Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%.<\/p>\n<p>In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P\/E of 55.4, below the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> The roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.<\/p>\n<p><strong>What to watch:<\/strong> Track how quickly new beds reach stable occupancy and whether average revenue per occupied bed keeps rising.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Dr_Lal_PathLabs_Features_Among_These_Large_Hospital_and_Pathology_Chain_Stocks\"><\/span><strong>Why Dr. Lal PathLabs Features Among These Large Hospital and Pathology Chain Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the premium hospital network shares on this list, Dr. Lal PathLabs is one of India&#8217;s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.<\/p>\n<p>In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%.<\/p>\n<p>Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P\/E of 56.6, below the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.<\/p>\n<p><strong>What to watch:<\/strong> Follow test volumes per patient and the balance between routine and specialised tests.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Krishna_Institute_of_Medical_Sciences_Features_Among_These_Large_Hospital_and_Pathology_Chain_Stocks\"><\/span><strong>Why Krishna Institute of Medical Sciences Features Among These Large Hospital and Pathology Chain Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Krishna Institute of Medical Sciences, known as KIMS Hospitals, runs a network of multi-specialty hospitals in Telangana, Andhra Pradesh and other states, with strengths in cardiac, neuro and transplant care.<\/p>\n<p>The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P\/E of 146.5, above the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.<\/p>\n<p><strong>What to watch:<\/strong> Track bed additions, occupancy and revenue per occupied bed.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Max_Healthcare_Institute_vs_Dr_Lal_PathLabs_vs_Krishna_Institute_of_Medical_Sciences_on_Key_Financials\"><\/span><strong>Max Healthcare Institute vs Dr. Lal PathLabs vs Krishna Institute of Medical Sciences on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three large hospital and pathology chain stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Max Healthcare Institute<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,059<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,536<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,442<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Dr. Lal PathLabs<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,140<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,864<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">510<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Krishna Institute of Medical Sciences<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,671<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,931<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">242<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Dr. Lal PathLabs posts the highest return on equity in this group at 20.1%. Max Healthcare Institute has the largest FY26 revenue at Rs 8,536 crore, and Krishna Institute of Medical Sciences shows the fastest revenue growth with a 23.8% compound annual rate. A useful habit with large hospital and pathology chain stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several diagnostic lab chain stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Max Healthcare Institute<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,064<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,407<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Dr. Lal PathLabs<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">698<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">830<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Krishna Institute of Medical Sciences<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">879<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,196<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Large_Hospital_and_Pathology_Chain_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Large Hospital and Pathology Chain Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these large hospital and pathology chain stocks, the main points are: Long-term premium hospital network shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio. Tracking promoter holding and management commentary adds context when you study premium hospital network shares.<\/p>\n<ul>\n<li><strong>Ramp-up timing.<\/strong> New hospitals take time to reach stable utilisation.<\/li>\n<li><strong>Doctor availability.<\/strong> Expert doctors are central to growth and hard to attract.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter large hospital and pathology chain stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Large_Hospital_and_Pathology_Chain_Stocks\"><\/span><strong>Final Thoughts on Large Hospital and Pathology Chain Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Large hospital and pathology chain stocks reward investors who follow bed additions, occupancy and test volumes together. Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences each have a clear expansion path. Based on the 21 October 2026 close, Max Healthcare Institute trades at Rs 819.9, Dr. Lal PathLabs at Rs 1,836.1 and Krishna Institute of Medical Sciences at Rs 674.1. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these large hospital and pathology chain stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track large hospital and pathology chain stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_large_hospital_and_pathology_chain_stocks\"><\/span><strong>What are large hospital and pathology chain stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Large hospital and pathology chain stocks are listed companies that run hospitals and diagnostic laboratories across several cities. Their earnings depend on bed capacity, occupancy, test volumes and the mix of procedures and tests. This list looks at three of them, Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_large_hospital_and_pathology_chain_stocks_are_covered_in_this_list\"><\/span><strong>Which large hospital and pathology chain stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences. Based on the 21 October 2026 close, Max Healthcare Institute traded at Rs 819.9, Dr. Lal PathLabs at Rs 1,836.1 and Krishna Institute of Medical Sciences at Rs 674.1. Their return on equity ranges from 10.7% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 23.8%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_large_hospital_and_pathology_chain_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do large hospital and pathology chain stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Large hospital and pathology chain stocks have a strong roadmap in India because rising health insurance cover and a preference for trusted providers are moving patients towards organised hospitals and labs. The main drivers are as follows. Insurance cover. More insured families choose organised providers for planned care. Capacity additions. New beds and collection centres lift volumes in proven cities. Preventive testing. Regular health checks raise the number of tests per person. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Max_Healthcare_Institute_performed_financially\"><\/span><strong>How has Max Healthcare Institute performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%. In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P\/E of 55.4, below the industry P\/E of 59.6. Looking ahead, the roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Dr_Lal_PathLabs_performed_financially\"><\/span><strong>How has Dr. Lal PathLabs performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P\/E of 56.6, below the industry P\/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Krishna_Institute_of_Medical_Sciences_performed_financially\"><\/span><strong>How has Krishna Institute of Medical Sciences performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P\/E of 146.5, above the industry P\/E of 59.6. Looking ahead, the company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_large_hospital_and_pathology_chain_stocks\"><\/span><strong>What risks should investors check before buying large hospital and pathology chain stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying large hospital and pathology chain stocks. Ramp-up timing. New hospitals take time to reach stable utilisation. Doctor availability. Expert doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_large_hospital_and_pathology_chain_stocks_investment_advice\"><\/span><strong>Is this list of large hospital and pathology chain stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are large hospital and pathology chain stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Large hospital and pathology chain stocks are listed companies that run hospitals and diagnostic laboratories across several cities. Their earnings depend on bed capacity, occupancy, test volumes and the mix of procedures and tests. This list looks at three of them, Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which large hospital and pathology chain stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences. Based on the 21 October 2026 close, Max Healthcare Institute traded at Rs 819.9, Dr. Lal PathLabs at Rs 1,836.1 and Krishna Institute of Medical Sciences at Rs 674.1. Their return on equity ranges from 10.7% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 23.8%.\"}},{\"@type\":\"Question\",\"name\":\"Why do large hospital and pathology chain stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Large hospital and pathology chain stocks have a strong roadmap in India because rising health insurance cover and a preference for trusted providers are moving patients towards organised hospitals and labs. The main drivers are as follows. Insurance cover. More insured families choose organised providers for planned care. Capacity additions. New beds and collection centres lift volumes in proven cities. Preventive testing. Regular health checks raise the number of tests per person. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Max Healthcare Institute performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%. In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P\/E of 55.4, below the industry P\/E of 59.6. Looking ahead, the roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.\"}},{\"@type\":\"Question\",\"name\":\"How has Dr. Lal PathLabs performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P\/E of 56.6, below the industry P\/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.\"}},{\"@type\":\"Question\",\"name\":\"How has Krishna Institute of Medical Sciences performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P\/E of 146.5, above the industry P\/E of 59.6. Looking ahead, the company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying large hospital and pathology chain stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying large hospital and pathology chain stocks. Ramp-up timing. New hospitals take time to reach stable utilisation. Doctor availability. Expert doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of large hospital and pathology chain stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Large Hospital and Pathology Chain Stocks with a strong future roadmap: Max Healthcare Institute, Dr. Lal PathLabs and Krishna Institute of Medical Sciences. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.<\/p>\n","protected":false},"author":29,"featured_media":323742,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,14766,8584,14767,14764,13896,14765],"class_list":["post-323743","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-diagnostic-lab-chain-stocks","tag-dr-lal-pathlabs-2","tag-krishna-institute-of-medical-sciences","tag-large-hospital-and-pathology-chain-stocks","tag-max-healthcare-institute","tag-premium-hospital-network-shares"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["323742"],"rank_math_title":["Large Hospital and Pathology Chain Stocks to Watch"],"rank_math_description":["Compare 3 large hospital and pathology chain stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 21 Oct 2026."],"rank_math_focus_keyword":["large hospital and pathology chain stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-premium-hospital-network-pathology-lab-chain-and-regional-multi-specialty.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=323743"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323743\/revisions"}],"predecessor-version":[{"id":323744,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323743\/revisions\/323744"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/323742"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=323743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=323743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=323743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}